Effect of pharmacologically induced smooth muscle activation on permeability in murine colitis

Mediators of Inflammation

Volumn 12, Issue 1, 2003, Pages 21-27

  Zijlstra, Freek J ^a   Van Meeteren, Marieke E ^b   Garrelds, Ingrid M ^a   Meijssen, Maarten A C ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NUMICO RESEARCH   (Netherlands)

^c NONE

Author keywords

Dextran sulphate sodium; Inflammation; Intestinal motility; Intestinal permeability; Mice

Indexed keywords

1 (3 CHLOROPHENYL)BIGUANIDE; CARBACHOL; DEXTRAN SULFATE; PHENYLEPHRINE; SALBUTAMOL;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCENDING COLON; COLITIS; CONTROLLED STUDY; DESCENDING COLON; FEMALE; ILEUM; INFLAMMATION; INTESTINE CONTRACTION; INTESTINE MOTILITY; INTESTINE MUCOSA PERMEABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SMOOTH MUSCLE CONTRACTILITY; SMOOTH MUSCLE RELAXATION;

ALBUTEROL; ANIMALS; BIGUANIDES; CARBACHOL; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FEMALE; INTESTINAL ABSORPTION; MICE; MICE, INBRED BALB C; MUSCLE CONTRACTION; MUSCLE RELAXATION; MUSCLE, SMOOTH; ORGAN CULTURE TECHNIQUES; PERMEABILITY; PHENYLEPHRINE;

ANIMALIA; MURINAE;

EID: 0038672090     PISSN: 09629351     EISSN: None     Source Type: Journal    
DOI: 10.1080/0962935031000096944     Document Type: Article

References (36)

1. Russel MG, Stockbrugger RW. Epidemiology of inflammatory bowel disease: an update. Scand J Gastroenterol 1996; 31: 417-427.
2. Satsangi J, Welsh KI, Bunce M, Julier C, Farrant JM, Bell JL, Jewell DP. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 1996; 347: 1212-1217.
3. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115: 182-205.
4. 51Cr-labelled ethylenediaminetetraacetate in inflammatory bowel disease. Gastroenterology 1983; 85: 318-322.
5. Munkholm P, Langholz E, Hollander D, Thornberg K, Orholm M, Katz KD, Binder V. Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first degree relatives. Gut 1994; 35: 68-72.
6. Nejdfors P, Wang Q, Ekelund M, et al. Increased colonic permeability in patients with ulcerative colitis: an in vitro study. Scand J Gastroenterol 1998; 33: 749-753.
7. 51Cr-EDTA in patients with active inflammatory bowel disease. Clin Invest Med 1988; 11: 151-155.
8. Nielsen OH, Rask-Madsen J. Mediators of inflammation in chronic inflammatory bowel disease. Scand J Gastroenterol Suppl 1996; 216: 149-159.
9. Sanderson IR, Walker WA. Uptake and transport of macromolecules by the intestine: possible role in clinical disorders (an update). Gastroenterology 1993; 104: 622-639.
10. Snape Jr WJ, Kao HW. Role on inflammatory mediators in colonic smooth muscle function in ulcerative colitis. Dig Dis Sci 1988; 33: 65S-70S.
11. Reddy SN, Bazzocchi G, Chan S, et al. Colonic motility and transit in health and ulcerative colitis. Gastroenterology 1991; 101: 1289-1297.
12. Collins SM. The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology 1996; 111: 1683-1699.
13. Hosseini JM, Goldhill JM, Bossone C, Pineiro, Carrero V, Shea-Donohue T. Progressive alterationbs in circular smooth muscle contractility in TNBS-induced colitis in rats. Neurogastroenterol Motil 1999; 11: 347-356.
14. Travis S, Menzies I. Intestinal permeability: functional assessment and significance. Clin Sci 1992; 82: 471-488.
15. Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: an overview. Gastroenterology 1995; 108: 1566-1581.
16. Katz KD, Hollander D, Vadheim CM, et al. Intestinal permeability in patients with Crohn's disease and their healthy relatives. Gastroenterology 1989; 97: 927-931.
17. Howden CW, Robertson C, Duncan A, Morris AJ, Russell RI. Comparison of different measurements of intestinal permeability in inflammatory bowel disease. Am J Gastroenterol 1991; 86: 1445-1449.
18. Hollander D. The intestinal permeability barrier. A hypothesis as to its regulation and involvement in Crohn's disease. Scand J Gastroenterol 1992; 27: 721-726.
19. Van Meeteren ME, van Bergeijk JD, van Dijk APM, Tak CJAM, Meijssen MAC, Zijlstra FJ. Intestinal permeability and contractility in murine colitis. Mediators Inflamm 1998; 7: 163-168.
20. Okayasu I, Hatakeyama S, Jamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990; 98: 694-702.
21. Zijlstra FJ, van Dijk APM, Wilson JHP. Increased platelet activating factor synthesis in experimental colitis after diclofenac and 5-amino-salicylic acid. Eur J Pharmacol 1993; 249: R1-R2.
22. Van Bergeijk JD, van Westreenen H, Adhien P, Zijlstra FJ. Diminished nitroprusside-induced relaxation of inflamed colonic smooth muscle in mice. Mediat Inflamm 1998; 7: 283-287.
23. Van Dijk APM, Keuskamp ZJ, Wilson JHP, Zijlstra FJ. Sequential release of cytokines, lipid mediators and nitric oxide in experimental colitis. Mediat Inflamm 1995; 4: 186-190.
24. Zijlstra FJ, Garrelds IM, van Dijk APM, Wilson JHP. Experimental colitis in mice: effects of olsalazine on eicosanoid production in colonic tissue. Agents Actions 1992; 38: C76-C78.
25. Van Meeteren ME, Meijssen MA, Zijlstra FJ. The effect of dexamethasone treatment on murine colitis. Scand J Gastroenterol 2000; 35: 517-521.
26. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulphate sodium experimental routine colitis. Lab Invest 1993; 69: 238-249.
27. Bijlsma PB, Peeters RA, Groot JA, Dekker PR, Taminiau JA, van der Meer R. Differential in vivo and in vitro intestinal permeability to lactulose and mannitol in animals and humans: a hypothesis. Gastroenterology 1995; 108: 687-696.
28. Krugliak P, Hollander D, Schaepfer CC, Nguyen H, Ma TY. Mechanisms and sites of mannitol permeability of small and large intestine in the rat. Dig Dis Sci 1994; 39: 796-801.
29. Myers BS, Dempsey DT, Yasar S, Martin JS, Parkman HP, Ryan JP. Acute experimental distal colitis alters colonic transit in rats. J Surg Res 1997; 69: 107-112.
30. Nolan JP, Hare DK, McDevitt JJ, Ali MV. In vitro studies of intestinal endotoxin absorption. I. Kinetics of absorption in the isolated everted gut sac. Gastroenterology 1977; 72: 434-439.
31. Yamamoto A, Utsumi E, Sakane T, Hamaura T, Nakamura J, Hashida M, Sezaki H. Immunological control of drug absorption from the gastrointestinal tract: the mechanism whereby intestinal anaphylaxis interferes with the intestinal absorption of bromthymol blue in the rat. J Pharm Pharmacol 1986; 38: 357-362.
32. Seidman EG, Hanson DG, Walker WA. Increased permeability to polyethylene glycol 4000 in rabbits with experimental colitis. Gastroenterology 1986; 90: 120-126.
33. Mullin JM, Marano CW, Laughin KV, Nuciglio M, Stevenson BR, Soler P. Different size limitations for increased transepithelial paracellular solute flux across phorbol ester and tumor necrosis factor-treated epithelial sheets. J Cell Physiol 1997; 171: 226-233.
34. Ameno H, Tani T, Hanasawa K, Kodama M. New method for the detection of bacterial translocation using intestinal permeability with polyethylene glycol 4000. Eur Surg Res 2000; 32: 23-29.
35. Sun Z, Wang X, Andersson R. Role of intestinal permeability in monitoring mucosal barrier function. History, methodology, and significance of pathophysiology. Dig Surg 1998; 15: 386-397.
36. Garrelds IM, Heiligers JPC, van Meeteren ME, Duncker DJ, Saxena PR, Meijssen MAC, Zijlstra FJ. Intestinal blood flow in murine colitis induced with dextran sulfate sodium. Dig Dis Sci 2002; 47: 2231-2236.